Literature DB >> 16014596

Contradicted and initially stronger effects in highly cited clinical research.

John P A Ioannidis1.   

Abstract

CONTEXT: Controversy and uncertainty ensue when the results of clinical research on the effectiveness of interventions are subsequently contradicted. Controversies are most prominent when high-impact research is involved.
OBJECTIVES: To understand how frequently highly cited studies are contradicted or find effects that are stronger than in other similar studies and to discern whether specific characteristics are associated with such refutation over time.
DESIGN: All original clinical research studies published in 3 major general clinical journals or high-impact-factor specialty journals in 1990-2003 and cited more than 1000 times in the literature were examined. MAIN OUTCOME MEASURE: The results of highly cited articles were compared against subsequent studies of comparable or larger sample size and similar or better controlled designs. The same analysis was also performed comparatively for matched studies that were not so highly cited.
RESULTS: Of 49 highly cited original clinical research studies, 45 claimed that the intervention was effective. Of these, 7 (16%) were contradicted by subsequent studies, 7 others (16%) had found effects that were stronger than those of subsequent studies, 20 (44%) were replicated, and 11 (24%) remained largely unchallenged. Five of 6 highly-cited nonrandomized studies had been contradicted or had found stronger effects vs 9 of 39 randomized controlled trials (P = .008). Among randomized trials, studies with contradicted or stronger effects were smaller (P = .009) than replicated or unchallenged studies although there was no statistically significant difference in their early or overall citation impact. Matched control studies did not have a significantly different share of refuted results than highly cited studies, but they included more studies with "negative" results.
CONCLUSIONS: Contradiction and initially stronger effects are not unusual in highly cited research of clinical interventions and their outcomes. The extent to which high citations may provoke contradictions and vice versa needs more study. Controversies are most common with highly cited nonrandomized studies, but even the most highly cited randomized trials may be challenged and refuted over time, especially small ones.

Mesh:

Year:  2005        PMID: 16014596     DOI: 10.1001/jama.294.2.218

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  306 in total

1.  Medical reversal: why we must raise the bar before adopting new technologies.

Authors:  Vinay Prasad; Adam Cifu
Journal:  Yale J Biol Med       Date:  2011-12

2.  The care and feeding of evidence based medicine.

Authors:  Frank L Tabrah
Journal:  Hawaii J Med Public Health       Date:  2012-04

3.  Putting ACCOMPLISH into context: management of hypertension in 2010.

Authors:  Finlay A McAlister; Robert J Herman; Nadia A Khan; Simon W Rabkin; Norm Campbell
Journal:  CMAJ       Date:  2010-09-13       Impact factor: 8.262

4.  Editor's Spotlight/Take 5: Do Orthopaedic Surgeons Acknowledge Uncertainty?

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2016-01-27       Impact factor: 4.176

5.  Replication and contradiction of highly cited research papers: a lesson for the Secretary of State for Health?

Authors:  Roxanne Keynejad; Clare Holt; Tony Rao
Journal:  BJPsych Bull       Date:  2015-12

6.  Arrhythmia & Electrophysiology Review - Do we Need Another Journal?

Authors:  Demosthenes Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2012-09

7.  Perspective: Limiting Dependence on Nonrandomized Studies and Improving Randomized Trials in Human Nutrition Research: Why and How.

Authors:  John F Trepanowski; John P A Ioannidis
Journal:  Adv Nutr       Date:  2018-07-01       Impact factor: 8.701

8.  Sepsis reconsidered: Identifying novel metrics for behavioral landscape characterization with a high-performance computing implementation of an agent-based model.

Authors:  Chase Cockrell; Gary An
Journal:  J Theor Biol       Date:  2017-07-18       Impact factor: 2.691

9.  Prediction of responders for outcome measures of locomotor Experience Applied Post Stroke trial.

Authors:  Bruce H K Dobkin; Stephen E Nadeau; Andrea L Behrman; Samuel S Wu; Dorian K Rose; Mark Bowden; Stephanie Studenski; Xiaomin Lu; Pamela W Duncan
Journal:  J Rehabil Res Dev       Date:  2014

10.  Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease.

Authors:  Christian Gluud; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav H Helø; Per Hildebrandt; Jørgen Hilden; Gorm Boje Jensen; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian M Jespersen
Journal:  Cardiology       Date:  2008-05-02       Impact factor: 1.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.